NCT01407523View on ClinicalTrials.gov

An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures

PHASE2CompletedINTERVENTIONAL
Enrollment

16

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
EpilepsyPartial Onset Seizures
Interventions
DRUG

Levetiracetam

"* Formulation: concentrate for solution for infusion~* Strength: Levetiracetam injection (100 mg/mL) will be packed in 5 mL glass vials (500 mg/5 mL)~* Dosage: 1000 mg/day, 1500 mg/day, 2000 mg/day, 2500 mg/day or 3000 mg/day~* Frequency: twice daily"

Trial Locations (4)

Unknown

1, Niigata

2, Shizuoka

3, Kodaira

4, Yamagata-city, Yamagata

All Listed Sponsors
lead

UCB Japan Co. Ltd.

INDUSTRY

NCT01407523 - An Open Label Study of L059 Intravenous (IV) in Japanese Epilepsy Subjects With Partial Onset Seizures | Biotech Hunter | Biotech Hunter